2017 Endocrine Board Review Course

2017 Endocrine Board Review Course
Welcome to the Endocrine Board Review 2017 live course Evaluation
Unlike other board preparation meetings, the Endocrine Society's Board Review Course offers a comprehensive mock-exam format, with case-based ABIM-style questions forming the bulk of the presentations. Each section follows the ABIM blueprint for the board exam, covering the breadth and depth of the certification/recertification examination. But you won't just get a right or wrong answer—each case will be discussed in detail, with the correct and incorrect answer options reviewed. You'll also have opportunities to ask questions directly to the faculty, and review detailed answer explanations, references, and a customized score report.
Learning Objectives
Upon completion of this educational activity, learners will be able to demonstrate enhanced medical knowledge and clinical skills across all major areas of endocrinology; apply knowledge and skills in diagnosing, managing, and treating a wide spectrum of endocrine disorders; and successfully complete the board examination for certification or recertification in the subspecialty of endocrinology, diabetes, and metabolism.
Additional Information
Day One – Tuesday, September 26, 2017 | |
---|---|
7:00–8:00 AM | Continental Breakfast |
8:00–8:15 AM | Welcome and Overview of the Certification Process David S. Cooper, MD |
8:15–9:45 AM | Diabetes Board Review |
9:45–10:00 AM | Q&A with Dr. Jabbour |
10:00–10:15 AM | BREAK/EXHIBITS |
10:15–11:30 AM | Adrenal Board Review Richard Auchus, MD, PhD |
11:30–11:45 AM | Q&A with Dr. Auchus |
11:45 AM –12:45 PM | LUNCH/EXHIBITS |
12:45–2:15 PM | Calcium and Bone Board Review Carolyn Becker, MD |
2:15–2:30 PM | Q&A with Dr. Becker |
2:30–2:45 PM | BREAK/EXHIBITS |
2:45–4:15 PM | Obesity/Lipids Board Review Andrea Coviello, MD |
4:15–4:30 PM | Q&A with Dr. Coviello |
4:30–4:45 PM | Wrap-up |
Day Two – Wednesday, September 27, 2017 | |
---|---|
7:00–8:00 AM | Continental Breakfast |
8:00–9:15 AM | Pituitary Board Review Mark Molitch, MD |
9:15–9:30 AM | BREAK |
9:30–11:15 AM | Diabetes Board Review, continued Michelle Magee, MD |
11:15–11:30 AM | Q&A with Dr. Magee |
11:30 AM–12:30 PM | LUNCH |
12:30–1:30 PM | Female Reproduction Board Review Margaret Wierman, MD |
1:30–1:45 PM | Q&A with Dr. Wierman |
1:45–2:45 PM | Male Reproduction Board Review Frances Hayes, MD |
2:45–3:00 PM | Q&A with Dr. Hayes |
3:00–3:15 PM | BREAK |
3:15–4:45 PM | Thyroid Board Review Elizabeth Pearce, MD |
4:45–5:00 PM | Q&A with Dr. Pearce |
5:00–5:15 PM | Wrap-up |
Endocrine Board Review Chair
David S. Cooper, MD – The Johns Hopkins University School of Medicine
Faculty Authors
Richard J. Auchus, MD, PhD – University of Michigan
Carolyn B. Becker, MD – Brigham and Women’s Hospital
Daniel H. Bessesen, MD – University of Colorado School of Medicine
Andrea D. Coviello, MD – Duke University School of Medicine
Frances J. Hayes, MD – Massachusetts General Hospital
Serge A. Jabbour, MD – Thomas Jefferson University Sidney Kimmel Medical College
Michelle F. Magee, MD – MedStar Washington Hospital Center and Georgetown University School of Medicine
Mark E. Molitch, MD – Northwestern University Feinberg School of Medicine
Elizabeth N. Pearce, MD, MSc – Boston University School of Medicine
Margaret E. Wierman, MD – University of Colorado School of Medicine
Medical Editor
Abbie L. Young, MS, CGC, ELS(D)
Disclosure Policy
The faculty, committee members, and staff who are in a position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Richard J. Auchus, MD, PhD: Contracted Research, Millendo Pharmaceuticals, Strongbridge Biopharma, Novartis Pharmaceuticals; Consultant, Alder Biopharmaceuticals, Corcept Pharmaceuticals, Diurnal Limited, Ipsen Pharmaceuticals, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Spruce Biosciences, Strongbridge Biopharma
Andrea D. Coviello, MD: Consultant and Speaker, Novo Nordisk Inc.
Serge A. Jabbour, MD: Consultant, AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals
Mark E. Molitch, MD: Consultant, Pfizer Inc.; Consultant and Primary Investigator, Chiasma, Inc., Ipsen Pharmaceuticals, Novartis Pharmaceuticals
Elizabeth N. Pearce, MD, Msc: Primary Investigator, Sociedad Química y Minera de Chile S.A.; Speaker, IBSA Institut Biochimique SA, Merck Serono
The following faculty reported no relevant financial relationships: Carolyn B. Becker, MD; David S. Cooper, MD; Frances J. Hayes, MD; Michelle F. Magee, MD; Margaret E. Wierman, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
CME & MOC
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification (MOC):
By attending the 2017 Endocrine Board Review, you are eligible to earn a maximum of 14.25 American Board of Internal Medicine (ABIM) Medical Knowledge MOC points.
In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:
- Provide your board-certification information in your educational profile
Available Credit
- 14.25 ABIM MOC
- 14.25 AMA PRA Category 1 Credits™
- 14.25 CME Certificate of Participation
Click the Start button to go to the evaluation.